268.65MMarket Cap-3442P/E (TTM)
5.450High5.065Low375.51KVolume5.150Open5.140Pre Close2.02MTurnover1.28%Turnover RatioLossP/E (Static)50.03MShares7.98052wk High29.03P/B158.19MFloat Cap3.24052wk Low--Dividend TTM29.46MShs Float18.170Historical High--Div YieldTTM7.49%Amplitude2.440Historical Low5.375Avg Price1Lot Size
scPharmaceuticals Stock Forum
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the Furoscix Indication in Heart Failure
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
scPharmaceuticals Inc. (SCPH) has secured non-dilutive financings totaling up to $125 million with Perceptive Advisors. The deal includes a $75 million senior secured loan and a $50 million revenue interest financing. Key benefits include:
1. Refinancing of existing debt with improved terms
2. Lower interest rate and extended interest-only period
3. Reduc...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 (Furosemide 80 mg/1 mL) Autoinjector
scPharmaceuticals Inc. (SCPH)announced positive topline results from a pharmacokinetic study of SCP-111, an investigational furosemide autoinjector. The study achieved its primary and secondary endpoints, demonstrating 107.3% bioavailability compared to IV furosemide. SCP-111 showed similar urine output and electrol...
No comment yet